Phreesia, Inc. (NYSE:PHR) Receives Consensus Recommendation of “Buy” from Analysts

Phreesia, Inc. (NYSE:PHR) has been assigned an average recommendation of “Buy” from the twelve ratings firms that are covering the firm, MarketBeat.com reports. Twelve investment analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $31.33.

Several analysts recently weighed in on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $33.00 target price (up previously from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. Robert W. Baird reduced their price objective on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Truist Financial lifted their price objective on shares of Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. JMP Securities reaffirmed a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a research report on Tuesday, December 10th. Finally, Canaccord Genuity Group increased their price target on shares of Phreesia from $34.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, March 13th.

Insider Activity at Phreesia

In related news, SVP Amy Beth Vanduyn sold 1,311 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $26.61, for a total transaction of $34,885.71. Following the transaction, the senior vice president now owns 115,633 shares of the company’s stock, valued at $3,076,994.13. This represents a 1.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP David Linetsky sold 11,685 shares of the company’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $27.48, for a total transaction of $321,103.80. Following the transaction, the senior vice president now directly owns 231,271 shares in the company, valued at approximately $6,355,327.08. This trade represents a 4.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 164,269 shares of company stock worth $4,661,469 in the last three months. Insiders own 5.80% of the company’s stock.

Hedge Funds Weigh In On Phreesia

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Johnson Financial Group Inc. grew its holdings in Phreesia by 381.3% in the fourth quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company’s stock valued at $28,000 after purchasing an additional 896 shares during the last quarter. R Squared Ltd acquired a new stake in Phreesia in the 4th quarter valued at about $30,000. BankPlus Trust Department acquired a new stake in Phreesia in the 4th quarter valued at about $34,000. Quarry LP increased its holdings in Phreesia by 210.9% during the 4th quarter. Quarry LP now owns 2,835 shares of the company’s stock valued at $71,000 after acquiring an additional 1,923 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new position in Phreesia during the fourth quarter worth about $76,000. 92.10% of the stock is owned by institutional investors and hedge funds.

Phreesia Stock Performance

Shares of PHR opened at $25.57 on Tuesday. Phreesia has a 1 year low of $17.07 and a 1 year high of $30.53. The stock has a market capitalization of $1.50 billion, a PE ratio of -17.40 and a beta of 1.03. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. The stock has a 50-day simple moving average of $27.35 and a 200-day simple moving average of $24.20.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.